RBC Capital analyst Luca Issi lowered the price target on Adverum Biotechnologies (NASDAQ: ADVM) to $10.00 (from $12.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Adverum Biotechnologies (ADVM) Misses Q3 EPS by 130cNovember 4, 2024 7:31 PM Form 10-Q Adverum Biotechnologies, For: Sep 30November 4, 2024 4:45 PM Form 8-K Adverum Biotechnologies, For: Nov 04November 4, 2024 4:43 PM Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated MilestonesNovember 4, 2024 4:39 PM